Vicinitas Therapeutics
Signal active
Organization
Contact Information
Overview
Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.
About
Industries
Biotechnology, Life Science, Therapeutics
Founded
2022
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Vicinitas Therapeutics headquartered in United States, North America, operates in the Biotechnology, Life Science, Therapeutics sector. The company focuses on Biotechnology and has secured $780.0M in funding across 12 round(s). With a team of 11-50 employees, Vicinitas Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Vicinitas Therapeutics, raised $65.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
1
Investors
6
Lead Investors
0
Total Funding Amount
$65.0M
Details
1
Vicinitas Therapeutics has raised a total of $65.0M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2022 | Early Stage Venture | 65.0M |
Investors
Vicinitas Therapeutics is funded by 9 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| George Golumbeski | - | FUNDING ROUND - George Golumbeski | 65.0M |
| Droia Ventures | - | FUNDING ROUND - Droia Ventures | 65.0M |
| The Mark Foundation for Cancer Research | - | FUNDING ROUND - The Mark Foundation for Cancer Research | 65.0M |
| Vicinitas Therapeutics | - | FUNDING ROUND - Vicinitas Therapeutics | 65.0M |
Recent Activity
There is no recent news or activity for this profile.